Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

• Päätekijät: Ivelina Gueorguieva (Tekijä), Ann Cleverly (Tekijä), Durisala Desaiah (Tekijä), Analia Azaro (Tekijä), Joan Seoane (Tekijä), Irene Braña (Tekijä), Elisabet Sicart (Tekijä), Colin Miles (Tekijä), Michael M Lahn (Tekijä), Malcolm I Mitchell (Tekijä), Jordi Rodon (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: BioExcel Publishing Ltd, 2016-12-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Objective: Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunise...